The waiting is over. Pharmacia Corp. has emerged as the winner in the battle for one of the industry's most sought-after Phase III products, Altana AG 's PDE 4 inhibitor roflumilast for COPD and asthma [See Deal]. Despite having little or no presence in the respiratory market, the US group fought off Novartis AG , Roche and Aventis SA to win worldwide co-development and marketing rights to a drug that many analysts predict will be a blockbuster. Bullish ones say it could reach €3 billion ($2.7 billion) by 2006.
Pharmacia will pay Altana an upfront fee—estimated at $35 million based on the $.02 charge that Pharmacia will take in...




